Biotinylated Human CD7 Protein
Catalog No: CD7-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD7 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ala26-Pro180 (UniProt accession: P09564).
Product Details
- Molecular Aliases
- CD7 molecule; CD7; LEU-9; Tp40; TP41; GP40; LEU9
- Protein Length
- Ala26-Pro180
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 19.3 kDa. Due to glycosylation, the protein migrates to 34-48 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CD7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CD7 is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human CD7, His Tag at 1 μg/ml (100 μl/well) on the streptavidin precoated plate (5 μg/ml). Dose response curve for Anti-CD7 Antibody, hFc Tag with the EC50 of 3.5 ng/ml determined by ELISA (QC Test).
Background
CD7, also known as Leu-9, is an approximately 40 kDa glycosylated and palmitoylated transmembrane protein in the immunoglobulin superfamily. CD7 is expressed on T cells, NK cells, myeloid progenitor cells, and CD19 B progenitor cells. Among CD8 T cells, the CD7-bright population preferentially contains naïve and memory cells, while more weak expressors are primarily effector cells.
References
- Gomes-Silva D, Srinivasan M, Sharma S, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies[J]. Blood, 2017:blood-2017-01-761320.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.